Eaton Vance Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $131M | Buy |
451,027
+1,336
| +0.3% | +$384K | 0.19% | 110 |
|
|
2022
Q2 | $127M | Buy |
449,691
+5,182
| +1% | +$1.39M | 0.18% | 126 |
|
|
2022
Q1 | $116M | Buy |
444,509
+55,553
| +14% | +$13.2M | 0.13% | 152 |
|
|
2021
Q4 | $85.4M | Sell |
388,956
-50,755
| -12% | -$9.87M | 0.1% | 197 |
|
|
2021
Q3 | $79.3M | Sell |
439,711
-250,320
| -36% | -$48.9M | 0.11% | 186 |
|
|
2021
Q2 | $139M | Sell |
690,031
-139,687
| -17% | -$29.2M | 0.19% | 120 |
|
|
2021
Q1 | $178M | Sell |
829,718
-33,012
| -4% | -$7.25M | 0.26% | 88 |
|
|
2020
Q4 | $204M | Buy |
862,730
+38,468
| +5% | +$8.83M | 0.32% | 66 |
|
|
2020
Q3 | $224M | Sell |
824,262
-11,969
| -1% | -$3.3M | 0.41% | 53 |
|
|
2020
Q2 | $243M | Sell |
836,231
-43,331
| -5% | -$11.7M | 0.49% | 42 |
|
|
2020
Q1 | $209M | Sell |
879,562
-32,269
| -4% | -$7.4M | 0.51% | 42 |
|
|
2019
Q4 | $200M | Sell |
911,831
-152,561
| -14% | -$30.9M | 0.39% | 62 |
|
|
2019
Q3 | $180M | Buy |
1,064,392
+205,262
| +24% | +$36.3M | 0.39% | 66 |
|
|
2019
Q2 | $158M | Sell |
859,130
-42,196
| -5% | -$7.38M | 0.35% | 75 |
|
|
2019
Q1 | $166M | Sell |
901,326
-5,497
| -0.6% | -$1.02M | 0.38% | 73 |
|
|
2018
Q4 | $150M | Buy |
906,823
+5,871
| +0.7% | +$1.02M | 0.39% | 67 |
|
|
2018
Q3 | $174M | Buy |
900,952
+63,266
| +8% | +$11.3M | 0.39% | 76 |
|
|
2018
Q2 | $142M | Sell |
837,686
-464,764
| -36% | -$72M | 0.34% | 84 |
|
|
2018
Q1 | $212M | Buy |
1,302,450
+653,859
| +101% | +$107M | 0.26% | 103 |
|
|
2017
Q4 | $97.2M | Buy |
648,591
+1,088
| +0.2% | +$161K | 0.24% | 112 |
|
|
2017
Q3 | $98.4M | Buy |
647,503
+23,514
| +4% | +$3.54M | 0.25% | 109 |
|
|
2017
Q2 | $80.4M | Buy |
623,989
+48,341
| +8% | +$5.82M | 0.21% | 126 |
|
|
2017
Q1 | $62.9M | Sell |
575,648
-1,742
| -0.3% | -$153K | 0.17% | 144 |
|
|
2016
Q4 | $42.5M | Sell |
577,390
-262,095
| -31% | -$21.3M | 0.12% | 171 |
|
|
2016
Q3 | $73.2M | Sell |
839,485
-155,472
| -16% | -$14.7M | 0.21% | 115 |
|
|
2016
Q2 | $85.6M | Buy |
994,957
+585,172
| +143% | +$50.6M | 0.25% | 108 |
|
|
2016
Q1 | $32.6M | Sell |
409,785
-117,660
| -22% | -$10.6M | 0.1% | 166 |
|
|
2015
Q4 | $66.4M | Buy |
527,445
+107,920
| +26% | +$13M | 0.2% | 121 |
|
|
2015
Q3 | $43.7M | Buy |
419,525
+153,139
| +57% | +$19.7M | 0.13% | 144 |
|
|
2015
Q2 | $32.9M | Sell |
266,386
-3,455
| -1% | -$435K | 0.1% | 169 |
|
|
2015
Q1 | $31.8M | Buy |
269,841
+49,747
| +23% | +$5.96M | 0.1% | 170 |
|
|
2014
Q4 | $26.1M | Sell |
220,094
-114,685
| -34% | -$12.9M | 0.08% | 191 |
|
|
2014
Q3 | $37.6M | Buy |
334,779
+189,606
| +131% | +$18.1M | 0.11% | 156 |
|
|
2014
Q2 | $13.7M | Buy |
145,173
+86,561
| +148% | +$6.07M | 0.04% | 268 |
|
|
2014
Q1 | $4.14M | Buy |
58,612
+49
| +0.1% | +$3.88K | 0.01% | 421 |
|
|
2013
Q4 | $4.35M | Buy |
58,563
+1,288
| +2% | +$89.7K | 0.01% | 409 |
|
|
2013
Q3 | $4.34M | Sell |
57,275
-37,789
| -40% | -$3.01M | 0.01% | 390 |
|
|
2013
Q2 | $7.59M | Buy |
+95,064
| New | +$7M | 0.02% | 303 |
|
Other funds holding VRTX
Eaton Vance Management's VRTX Position: Q3 2022 in Review
Eaton Vance Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.3% in Q3 2022, buying an estimated $384K and bringing the position to 451,027 shares worth $131M. The position accounts for 0.19% of the portfolio, ranked #110.
Eaton Vance Management first reported a position in VRTX in Q2 2013 and has held it in 38 quarters since. The position peaked at $243M in Q2 2020. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.
- Eaton Vance Management held 451,027 shares of Vertex Pharmaceuticals worth $131M as of Q3 2022.
- Eaton Vance Management bought 1,336 Vertex Pharmaceuticals shares in Q3 2022, an estimated $384K.
- Vertex Pharmaceuticals made up 0.19% of Eaton Vance Management's portfolio in Q3 2022, its #110 holding.
- Eaton Vance Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 38 quarters since.
- Eaton Vance Management's Vertex Pharmaceuticals position peaked at $243M in Q2 2020.
- 1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.